Featured Research

from universities, journals, and other organizations

Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer

Date:
August 28, 2008
Source:
Journal of the National Cancer Institute
Summary:
The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a reduced risk of basal cell or squamous cell skin cancers in US veterans, researchers report in the Aug. 26 online issue of the Journal of the National Cancer Institute.

The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was associated with a reduced risk of basal cell or squamous cell skin cancers in U.S. veterans, researchers report in the August 26 online issue of the Journal of the National Cancer Institute.

ACE inhibitors and ARBs are frequently prescribed medications for the treatment of high blood pressure. Data from in vitro cell studies and animal models suggest these drugs may slow tumor growth and inhibit angiogenesis. Additionally, some epidemiological studies in humans suggest that ACE inhibitors and ARBs may reduce the risk of nonmelanoma skin cancers.

To test this possibility more specifically, Jennifer Christian, Pharm.D., Ph.D., of the VA Medical Center and Brown University in Providence, R.I., and colleagues performed a cohort study including 1,051 veterans who were at increased risk of keratinocyte skin cancers, including basal cell carcinoma or squamous cell carcinoma. The participants were already enrolled in a VA Cooperative Studies Program trial aimed at testing the efficacy of a topical agent. The researchers collected data on ACE inhibitor and ARBs use from a Veterans Affairs pharmacy database.

With a median follow-up of 3.4 years, the researchers identified 472 cases of basal cell carcinoma, 309 squamous cell cancers, and 200 deaths in the study population. The group taking either an ACE inhibitor or ARBs had a 39 percent relative reduction in incidence of basal cell cancer and a 33 percent relative reduction in squamous cell cancers compared with nonusers. The absolute incidence of the two cancers together was 237 per 1,000 person-years in the ACE inhibitor or ARB users and 374 per 1,000 among nonusers.

The researchers concluded that the use of these agents was associated with a reduction in the risk of nonmelanoma skin cancers but noted that the exact mechanism of action behind the reduction is unknown. "We were surprised to find such a pronounced reduction in [basal cell carcinoma and squamous cell carcinoma] incidence in users of ACE inhibitors or ARBs in such a high-risk group over a short amount of time," the authors write. "Because individuals at normal risk of keratinocyte cancer were not included in our study, the extent to which the results might apply to such individuals is unknown."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial. Journal of the National Cancer Institute, 2008; 100:1223-1232 DOI: 10.1093/jnci/djn262

Cite This Page:

Journal of the National Cancer Institute. "Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer." ScienceDaily. ScienceDaily, 28 August 2008. <www.sciencedaily.com/releases/2008/08/080826190854.htm>.
Journal of the National Cancer Institute. (2008, August 28). Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2008/08/080826190854.htm
Journal of the National Cancer Institute. "Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080826190854.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins